Literature DB >> 2666577

The on-off phenomenon.

A J Lees1.   

Abstract

The on-off phenomenon is an almost invariable consequence of sustained levodopa treatment in patients with Parkinson's disease. Phases of immobility and incapacity associated with depression alternate with jubilant thaws. Both pharmacokinetic and pharmacodynamic factors are involved in its pathogenesis, but evidence is presented to indicate that the importance of levodopa handling has been underestimated and that progressive reduction in the storage capacity of surviving nigrostriatal dopamine terminals is not a critical factor. Re-distribution of levodopa dosage which may mean smaller, more frequent doses, or larger less frequent increments, may be helpful in controlling oscillations in some patients. Dietary protein restriction, the use of selegiline hydrochloride and bromocriptine may also temporarily improve motor fluctuations. New approaches to management include the use of subcutaneous apomorphine, controlled-release preparations of levodopa with a peripheral dopa decarboxylase inhibitor and the continuous intra-duodenal administration of levodopa.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2666577      PMCID: PMC1033307          DOI: 10.1136/jnnp.52.suppl.29

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  42 in total

1.  Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography.

Authors:  K L Leenders; W H Poewe; A J Palmer; D P Brenton; R S Frackowiak
Journal:  Ann Neurol       Date:  1986-08       Impact factor: 10.422

2.  Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.

Authors:  R Kurlan; A J Rubin; C Miller; L Rivera-Calimlim; A Clarke; I Shoulson
Journal:  Ann Neurol       Date:  1986-08       Impact factor: 10.422

3.  Diurnal responsiveness to apomorphine.

Authors:  S T Gancher; J G Nutt
Journal:  Neurology       Date:  1987-07       Impact factor: 9.910

4.  Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients.

Authors:  S T Gancher; J G Nutt; W R Woodward
Journal:  Neurology       Date:  1987-06       Impact factor: 9.910

5.  The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.

Authors:  R J Hardie; S L Malcolm; A J Lees; G M Stern; J G Allen
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

6.  Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations.

Authors:  C Stibe; A Lees; G Stern
Journal:  Lancet       Date:  1987-04-11       Impact factor: 79.321

7.  Plasma levodopa, dopamine and therapeutic response following levodopa therapy of Parkinsonian patients.

Authors:  M N Rossor; J Watkins; M J Brown; J L Reid; C T Dollery
Journal:  J Neurol Sci       Date:  1980-06       Impact factor: 3.181

8.  Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations.

Authors:  W H Poewe; A J Lees; G M Stern
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

9.  Plasma levels of amino acids correlate with motor fluctuations in parkinsonism.

Authors:  J H Pincus; K M Barry
Journal:  Arch Neurol       Date:  1987-10

10.  The impact of treatment with levodopa on Parkinson's disease.

Authors:  K M Shaw; A J Lees; G M Stern
Journal:  Q J Med       Date:  1980
View more
  32 in total

Review 1.  Bromocriptine for levodopa-induced motor complications in Parkinson's disease.

Authors:  J J van Hilten; C Ramaker; W J Van de Beek; M J Finken
Journal:  Cochrane Database Syst Rev       Date:  2000

2.  The clinical use of apomorphine in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; C D Marsden
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

3.  Glutathione peroxidase in early and advanced Parkinson's disease.

Authors:  P Johannsen; G Velander; J Mai; E B Thorling; E Dupont
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

Review 4.  Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.

Authors:  H M Bryson; R J Milne; P Chrisp
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

Review 5.  The use of thalamotomy in the treatment of levodopa-induced dyskinesia.

Authors:  R D Page
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

6.  A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

Authors:  J L Montastruc; O Rascol; J M Senard; A Rascol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

Review 7.  A risk-benefit assessment of drugs used in the management of Parkinson's disease.

Authors:  I Y Bodagh; D R Robertson
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

Review 8.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 9.  Neuroimaging of Parkinson's disease: Expanding views.

Authors:  Carol P Weingarten; Mark H Sundman; Patrick Hickey; Nan-kuei Chen
Journal:  Neurosci Biobehav Rev       Date:  2015-09-26       Impact factor: 8.989

Review 10.  Idiopathic Parkinson's disease: epidemiology, diagnosis and management.

Authors:  Y Ben-Shlomo; K Sieradzan
Journal:  Br J Gen Pract       Date:  1995-05       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.